ALNY Down Despite Positive Data From Heart Disease Drug Study
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
| Ticker |
Sentiment |
Impact |
|
ALNY
|
Neutral
|
12 %
|
|
KRYS
|
Somewhat Bullish
|
24 %
|
|
ILMN
|
Neutral
|
18 %
|
|
FULC
|
Neutral
|
24 %
|
